Patricia Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Patricia Almeida has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Chung
Division of Pediatric Gastroenterology, Faculty of Medicine, University of Alberta, Edmonton, Canada
1 shared publication - Alexandra Petrova
Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada
1 shared publication - Daniela Migliarese Isaac
Division of Pediatric Gastroenterology and Nutrition, Stollery Children's Hospital, Edmonton, Alberta, Canada
1 shared publication - Diane R. Mould
Projections Research, Inc. Phoenixville Pennsylvania USA
1 shared publication - Eytan Wine
University of Alberta
1 shared publication - Hien Quoc Huynh
Edmonton Pediatric IBD Clinic (EPIC), Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, University of Alberta , Edmonton, Alberta
1 shared publication
Latest Publications
- 23 December 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (5) , 1995-2005
Early Infliximab Clearance Predicts Remission in Children with Crohn’s Disease
Background and Aims Children with Crohn’s disease have lower response rates to infliximab, lower infliximab levels, and higher infliximab clearance on weight-based dosing than adults. We hypothesize infliximab clearance is a predictive of later outcomes on infliximab in children with Crohn’s disease. Methods In this single-center retrospective study, data were collected from charts on diagnosis, anthropometry, routine labs, infliximab therapeutic drug monitoring, infliximab dosing, disease activity, and other treatments. With these data we generated a population pharmacokinetic model using non-linear mixed effects modeling and calculated infliximab clearance for each patient over time. Patients were classified as in remission, responder-only or non-responder at 5, 10 and 16 months. Regression and ROC analyses were used to assess for early predictors of remission and response to infliximab. Results Eighty-five subjects were included, with a median follow-up of 22.3 months (IQR 10.1–36.8). Our pharmacokinetic model showed infliximab clearance was positively associated with CRP and weight, while negatively associated with albumin. In regression analyses, early infliximab clearance was the only significant, consistent predictor of remission. A 0.1 L/day increase in infliximab clearance predicted remission with an OR between 0.179 and 0.426. Differences in dosing did not account for differences in outcome. Infliximab clearance alone had moderate predictive accuracy of remission, with an AUC between 0.682 and 0.738. Conclusions Early infliximab clearance is strongly associated with remission in children with Crohn’s disease. It may be useful as a marker of response in proactive therapeutic drug monitoring to guide early dose optimization and/or changes in treatment for betterment of long-term outcomes.
- 23 December 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (5) , 1995-2005
Early Infliximab Clearance Predicts Remission in Children with Crohn’s Disease
Background and Aims Children with Crohn’s disease have lower response rates to infliximab, lower infliximab levels, and higher infliximab clearance on weight-based dosing than adults. We hypothesize infliximab clearance is a predictive of later outcomes on infliximab in children with Crohn’s disease. Methods In this single-center retrospective study, data were collected from charts on diagnosis, anthropometry, routine labs, infliximab therapeutic drug monitoring, infliximab dosing, disease activity, and other treatments. With these data we generated a population pharmacokinetic model using non-linear mixed effects modeling and calculated infliximab clearance for each patient over time. Patients were classified as in remission, responder-only or non-responder at 5, 10 and 16 months. Regression and ROC analyses were used to assess for early predictors of remission and response to infliximab. Results Eighty-five subjects were included, with a median follow-up of 22.3 months (IQR 10.1–36.8). Our pharmacokinetic model showed infliximab clearance was positively associated with CRP and weight, while negatively associated with albumin. In regression analyses, early infliximab clearance was the only significant, consistent predictor of remission. A 0.1 L/day increase in infliximab clearance predicted remission with an OR between 0.179 and 0.426. Differences in dosing did not account for differences in outcome. Infliximab clearance alone had moderate predictive accuracy of remission, with an AUC between 0.682 and 0.738. Conclusions Early infliximab clearance is strongly associated with remission in children with Crohn’s disease. It may be useful as a marker of response in proactive therapeutic drug monitoring to guide early dose optimization and/or changes in treatment for betterment of long-term outcomes.